CDAC targeting EGFR mutant BG-60366

{
  "id": "MLC-T-ONC-012427",
  "term": "CDAC targeting EGFR mutant BG-60366",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable chimeric degradation activation compound (CDAC) targeting mutant epidermal growth factor receptor (EGFR) comprised of an E3 ubiquitin ligase ligand conjugated to an EGFR mutant-binding ligand, with potential antineoplastic activity. Upon oral administration, CDAC targeting EGFR mutant BG-60366 specifically targets and binds, with its mutant EGFR-targeting moiety, to mutant EGFR and the E3 ubiquitin ligase ligand moiety binds to E3 ubiquitin ligase. This catalyzes ubiquitination and proteasome-mediated degradation of mutant EGFR and prevents the activation of the EGFR-mediated signaling pathway. This leads to an inhibition of the growth of EGFR mutant-expressing tumor cells. EGFR is overexpressed or mutated in a variety of cancer cells.",
  "synonyms": [
    "CDAC BG-60366",
    "EGFR mutant degrader BG-60366",
    "EGFR mutation-targeted chimeric degradation activation compound BG-60366",
    "mutant EGFR-targeted CDAC BG-60366"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cdac-targeting-egfr-mutant-bg-60366/"
}